Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 7.76B P/E 57.04 EPS this Y - Ern Qtrly Grth -
Income 111.71M Forward P/E - EPS next Y - 50D Avg Chg -5.00%
Sales 541.24M PEG - EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book 8.85 EPS next 5Y - 52W High Chg -14.00%
Recommedations - Quick Ratio 2.33 Shares Outstanding 329.22M 52W Low Chg 61.00%
Insider Own - ROA 1.83% Shares Float 254.93M Beta 0.85
Inst Own - ROE 16.82% Shares Shorted/Prior 48.65K/50.87K Price 22.96
Gross Margin 23.83% Profit Margin 20.64% Avg. Volume 108,413 Target Price -
Oper. Margin 7.59% Earnings Date - Volume 344 Change -0.04%
About EVOTEC SE

Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE has a strategic collaboration with the University Hospital Erlangen regarding molecular analyses of biospecimens from the German chronic kidney disease cohort study. The company was founded in 1993 and is headquartered in Hamburg, Germany.

EVTCY Chatroom

User Image J_R_Nixon Posted - 9 years ago

$EVTCY Evotec alliance with $SNY Sanofi -> next step 5€ http://stks.co/c1vSN

User Image StreetwiseReports Posted - 02/26/15

How to Beat the Herd Mentality: Interview w/ Highline Research's Michael Higgins: http://stks.co/q1aOV $ALKS $EVTCY $MNKD $SVRA $TTNP

User Image LipperAlpha Posted - 10 years ago

Does $EVTCY have the answers needed to deliver cost-effective development services? http://stks.co/i1OP8 http://stks.co/i1OP9

User Image BidnessEtc Posted - 10 years ago

Sanofi SA $SNY Outsources Research Facility To Evotec $EVTCY http://stks.co/q15yt

User Image J_R_Nixon Posted - 10 years ago

$EVTCY Evotec and $SNY Sanofi enter into exclusive negotiations for a major multi-component strategic collaboration http://stks.co/i1N5a

User Image HaldenZimmermann Posted - 10 years ago

"@Biobull: $MNKD $SNY Buys $EVTCY. They specialize in oncology, neuroscience, and diabetes. http://stks.co/b1JRN"

User Image Biobull Posted - 10 years ago

$MNKD $SNY Buys $EVTCY. They specialize in oncology, neuroscience, and diabetes. http://stks.co/h1NCc

User Image J_R_Nixon Posted - 08/27/14

$GSK GlaxoSmithKline interested in German drug discovery group Evotec $EVTCY

User Image J_R_Nixon Posted - 10 years ago

$EVTCY Commerzbank hebt Evotec auf 'Buy' und Ziel auf 5 Euro http://stks.co/g0vDS

User Image datajunkies Posted - 15 years ago

NASDAQ 3 biggest decliners: $PRXI -13.74%, $HILL -12.40%, $EVTCY -11.39%, Fueled by NASDAQ Last Sale http://bit.ly/datajunkies

User Image datajunkies Posted - 15 years ago

NASDAQ 3 biggest decliners: $PRXI -11.88%, $UCBH -11.30%, $EVTCY -11.23%, Fueled by NASDAQ Last Sale http://bit.ly/datajunkies